oa SA Pharmaceutical Journal - New drug focus



Extracted from text ... SA Pharmaceutical Journal - June 2006 36 Evidence of efficacy The addition of aprepitant to standard anti-emetic therapy significantly improves emesis protection in general and, in particular, in the delayed phase by approximately 20%. Results from a recently published study in patients receiving moderately emetogenic chemotherapy suggest a benefit of aprepitant when combined with dexamethasone and a 5-HT3 receptor antagonist for the prevention of acute emesis, followed by aprepitant as a single agent in the prevention of delayed emesis. Altogether, the addition of aprepitant to the standard anti-emetic regimen (5-HT3 receptor antagonist and dexamethasone) significantly improves the protection against vomiting ..


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error